N@N

ASX, MTXX, PACR, NEXM, CYTR, RAD. Top Gainers With Lowest Price Friction In Morning Trade Today

^{Published on 2009-06-30 08:30:30, Last Modified on 2010-12-22 14:19:58 - WOPRAI}
 

June 30, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for June 30, 2009. Since late October market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This afair market makinga requirement is designed to prevent market makers from manipulating stock prices. Here is a list of the top companies with the largest gains this morning and lowest price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Advanced Semiconductor Engineering (NYSE: ASX), Matrixx Initiatives (NASDAQ: MTXX), Pacer International (NASDAQ: PACR), NexMed (NASDAQ: NEXM), CytRx Corp (NASDAQ: CYTR) and Rite Aid (NYSE: RAD). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

Symbol Change % BuyVol Buy% SellVol Sell% NetVol Friction

ASX $0.14 5.09% 81,507 56.60% 41,777 29.01% 39,730 2,838

MTXX $0.13 2.36% 103,815 61.77% 64,047 38.11% 39,768 3,059

PACR $0.13 6.22% 187,212 52.84% 166,594 47.02% 20,618 1,586

NEXM $0.11 30.59% 3,657,218 53.69% 3,154,925 46.31% 502,293 45,663

CYTR $0.09 9.47% 270,625 62.83% 160,076 37.17% 110,549 12,283

RAD $0.08 5.52% 2,626,241 56.83% 1,994,732 43.17% 631,509 78,939

Click here to view chart:

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar gains (Change) and very low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows ASX with a dollar gain this morning of +$0.14 and a Friction Factor of 2,838 shares. That means that it only takes 2,838 more shares of buying than selling to move ASX higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

Advanced Semiconductor Engineering, Inc. (NYSE: ASX), together with its subsidiaries, provides semiconductor packaging and testing services for semiconductor companies. Its services include semiconductor packaging; design and production of interconnect materials; front-end engineering testing; and wafer probing and final testing services. The company offers various leadframe-based package types, such as quad flat package, thin quad flat package, bump chip carrier, and quad flat no-lead package; and package types based on substrates, including flip-chip BGA and other BGA types, as well as wafer-bumping products. Its testing services comprise front-end engineering testing, wafer probing, and final testing of logic/mixed-signal and memory semiconductors, as well as other test-related services, such as burn-in testing, dry pack, and tape and reel. The company packages and tests a range of products for use in various end-use applications in communications, personal computers, consumer electronics, and industrial and automotive sectors. Advanced Semiconductor Engineering sells its products primarily in Taiwan, the United States, Asia, and Europe. The company was founded in 1984 and is based in Kaohsiung, Taiwan.

Matrixx Initiatives, Inc. (NASDAQ: MTXX), through its subsidiaries, engages in the development, production, marketing, and sale of over-the-counter (OTC) healthcare products. It offers Zicam Cold Remedy nasal pump, a homeopathic nasal gel that reduces the duration and severity of the common cold; Zicam Cold Remedy Swabs for consumers, who dislike nasal sprays; and Zicam Cold Remedy Chewables, Zicam Cold Remedy RapidMelts, Zicam Cold Remedy Oral Mist, Zicam Cold Remedy RapidMelts + Vitamin C, and Zicam Cold Remedy RapidMelts + Vitamin C and Echinacea, which are oral cold remedy products that deliver a dose of ionic zinc to the oral mucosa. The company also provides Zicam Allergy Relief, a homeopathic nasal gel formula to control allergy symptoms for sufferers of hay fever and upper respiratory allergies; Zicam Extreme Congestion Relief, a nasal gel for relief of nasal congestion and sinus pressure; and Zicam Sinus Relief that provides the benefit of the product with the aromatic strength of a cooling menthol/eucalyptus blend. In addition, it offers Zicam Cough Spray products to deliver cough relief and soothe throat irritation, including Zicam Cough Max, a liquid spray formulation that provides relief. Further, the company offers Zicam Multi-Symptom Cold and Flu Relief products, which utilize a spoon dosing delivery to provide relief of cold and flu symptoms; and Xcid, a creamy antacid product. It sells products directly to food, drug, mass market, and wholesale warehouse retailers in the United States, as well as to distributors that sell to retail establishments under the Zicam, Nasal Comfort, and Xcid brands. The company was formerly known as Gum Tech International, Inc. and changed its name to Matrixx Initiatives, Inc. in June 2002. Matrixx Initiatives, Inc. was founded in 1991 and is based in Scottsdale, Arizona.

Pacer International, Inc. (NASDAQ: PACR) operates as a non-asset based third-party logistics provider in North America. The company operates in two segments, Intermodal and Logistics. The Intermodal segment provides stacktrain, rail brokerage, and local cartage services principally to intermodal marketing companies, truck brokers, truckload carriers, automotive intermediaries, and international shipping companies. This segment also offers ramp-to-ramp and door-to-door services. As of December 26, 2008, the companya�s equipment fleet consisted of 1,849 double-stack railcars, 28,681 containers, and 29,904 chassis. The Logistics segment provides highway brokerage and truck services, international freight forwarding, warehousing and distribution, and supply chain management services to end-user customers. This segment also offers airfreight forwarding services as an indirect air carrier. The company was founded in 1974 and is headquartered in Concord, California.

NexMed, Inc. (NASDAQ: NEXM), a pharmaceutical and medical technology company, engages in the development of topical pharmaceutical products based on its proprietary NexACT transdermal drug delivery technology. The NexACT transdermal drug delivery technology is designed to enhance the absorption of an active drug through the skin and enable concentrations of the active drug to penetrate the desired site of the skin or extremity. The companya�s products under development include NM100060, a topical nail solution for the treatment of onychomycosis; Vitaros, a topical alprostadil-based cream treatment for patients with erectile dysfunction; and Femprox, an alprostadil-based cream product for the treatment of female sexual arousal disorder. It also focuses on the development of topical treatments for psoriasis. The company has a licensing agreement with Novartis International Pharmaceutical Ltd. for the development, manufacture, and commercialization of NM100060. NexMed, Inc. was founded in 1987 and is based in East Windsor, New Jersey.

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company, engages in the development of human therapeutics. Its product pipeline includes Tamibarotene, a synthetic retinoid in Phase II clinical development to treat acute promyelocytic leukemia; INNO-2006, a pro-drug for doxorubicin in Phase II clinical development for the treatment of cancer; Bafetinib, a drug in Phase I clinical development to treat chronic myeloid leukemia; Arimoclomol, an orally-administered small-molecule product candidate in Phase IIb clinical development for the treatment of amyotrophic lateral sclerosis; and Iroxanadine, an orally-administered small-molecule product candidate in Phase I clinical development to treat diabetic ulcers. The company also engages in developing treatments for neurodegenerative and other disorders based on its small-molecule molecular chaperone amplification technology; and new-drug discovery research utilizing its master chaperone regulator assay technology. The company was founded in 1985 and is headquartered in Los Angeles, California.

Rite Aid Corporation (NYSE: RAD), through its subsidiaries, operates retail drugstores. Its drugstores primarily provide pharmacy services. The company sells prescription drugs and front-end products. It offers approximately 28,000 front-end products, which include over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, beverages, convenience foods, greeting cards, seasonal merchandise, and various other everyday and convenience products, as well as photo processing. Rite Aid Corporation markets its products primarily under the Rite Aid brand. It sells its products to the customers covered by health plan contracts, which contract with a third party payors, such as an insurance companies, governmental agencies, health maintenance organizations, and other managed care providers. As of February 28, 2009, the company operated 4,901 stores in 31 states across the country and in the District of Columbia. It has a strategic alliance with GNC to operate GNC stores within Rite Aid stores. Rite Aid Corporation was founded in 1927 and is headquartered in Camp Hill, Pennsylvania.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,550,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. None of the companies in this report have paid to be included in this report. From time to time we will mention a company that may have previously paid $995 per month for market data purchased from BUYINS.NET. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET, FRICTION FACTOR and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net